T cell receptor alpha variable 41Genealiases: TCRAV19S1 · TCRAV41S1
Q-omics provides the consensus-scored TRAV41 profile across patient tissues and cancer cell-line models. TRAV41 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAV41 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TRAV41 RNA expression shows 14,049 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TRAV41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV41 survival associations across molecular data types. TRAV41 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV41 RNA expression–survival associations across cancer types. High TRAV41 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, CESC, PAAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAV41 RNA expression.
This table summarizes TRAV41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV41 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, BRCA, STAD and READ. The KIRC box plot shows higher TRAV41 RNA expression in tumor versus normal tissue (log2 FC = +0.937, t-test p < 0.001).
This table shows molecular features associated with TRAV41 in patient tissues and cancer cell lines. In patient samples, TRAV41 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
